Skip to the page

Data / Drug companies / Posaconazole

Posaconazole: 29 companies and 36 products in the FDA NDC directory

Posaconazole is listed in the FDA National Drug Code Directory by 29 companies, with 36 products in commercial distribution. 30 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, delayed release; injection, solution; solution, and the newest product started marketing on February 24, 2025.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
29
Products
36
Generic (ANDA) products
30 (83.3%)
Application numbers
21
Routes
Oral, Intravenous
Brand names
Noxafil
openFDA record search
api.fda.gov

Companies that list posaconazole

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
Merck Sharp & Dohme LLC4suspension; tablet, coatedNew drug applications (NDA)June 8, 2021
Bryant Ranch Prepack2tablet, delayed releaseGeneric drugs (ANDA)September 15, 2023
Camber Pharmaceuticals, Inc.2solution; tablet, delayed releaseGeneric drugs (ANDA)December 23, 2024
Glenmark Pharmaceuticals Inc., USA2injection, solutionGeneric drugs (ANDA)July 1, 2024
Par Health USA, LLC2suspension; tablet, coatedAuthorized generics (NDA)March 29, 2023
A2A Integrated Pharmaceuticals1tablet, delayed releaseGeneric drugs (ANDA)May 16, 2024
American Health Packaging1tablet, delayed releaseGeneric drugs (ANDA)June 11, 2020
Amneal Pharmaceuticals NY LLC1tablet, delayed releaseGeneric drugs (ANDA)December 30, 2022
Atlantic Biologicals Corp.1tablet, delayed releaseGeneric drugs (ANDA)August 28, 2019
Aurobindo Pharma Limited1tablet, delayed releaseGeneric drugs (ANDA)July 18, 2024
AvKARE1tablet, delayed releaseGeneric drugs (ANDA)April 20, 2023
AvPAK1tablet, delayed releaseGeneric drugs (ANDA)May 9, 2022
Biocon Pharma Inc.1tablet, delayed releaseGeneric drugs (ANDA)March 8, 2022
Bryant Ranch Prepack1tablet, delayed releaseGeneric drugs (ANDA)September 15, 2023
Dr. Reddy's Laboratories Inc.1tablet, delayed releaseGeneric drugs (ANDA)April 7, 2022
Eugia US LLC1injectionGeneric drugs (ANDA)December 26, 2023
Fresenius Kabi USA, LLC1injection, solutionGeneric drugs (ANDA)December 26, 2023
Gland Pharma Limited1injection, solutionGeneric drugs (ANDA)December 26, 2023
Golden State Medical Supply, Inc.1tablet, delayed releaseGeneric drugs (ANDA)May 10, 2022
Hikma Pharmaceuticals USA Inc.1suspensionGeneric drugs (ANDA)March 29, 2023
I3 Pharmaceuticals, LLC1tablet, delayed releaseGeneric drugs (ANDA)September 15, 2023
Lannett Company, Inc.1tablet, delayed releaseGeneric drugs (ANDA)August 28, 2019
Lupin Pharmaceuticals, Inc.1tablet, delayed releaseGeneric drugs (ANDA)February 17, 2021
Major Pharmaceuticals1tablet, delayed releaseGeneric drugs (ANDA)February 3, 2021
Mylan Institutional LLC1solutionGeneric drugs (ANDA)March 22, 2024
NorthStar Rx LLC1tablet, delayed releaseGeneric drugs (ANDA)April 2, 2023
Novadoz Pharmaceuticals LLC1tablet, coatedGeneric drugs (ANDA)February 24, 2025
Par Health USA, LLC1injectionGeneric drugs (ANDA)January 1, 2023
SpecGx LLC1tablet, delayed releaseGeneric drugs (ANDA)May 10, 2022

Dosage forms

Dosage formProductsShare
Tablet, delayed release2055.6%
Injection, solution411.1%
Solution38.3%
Suspension38.3%
Tablet, coated38.3%
Injection25.6%
Powder, for suspension12.8%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)3083.3%
New drug applications (NDA)411.1%
Authorized generics (NDA)25.6%

Pharmacologic classes

ClassProducts
Azole Antifungal36

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.